News for Immutep Limited (PRRUF)

**media[637926]**

Immutep Limited (IMMP) has reported promising outcomes from the INSIGHT-003 study, which is examining the effectiveness of eftilagimod alpha combined with KEYTR

Immutep's eftilagimod shows a 17.6-month survival benefit in head and neck cancer. Find out how and why IMMP is continuing to develop in the right direction.

U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday. Shares of Ichor Holdings, Ltd. ICHR fell sharply in today'...

Key Highlights: Immutep Limited reports a remarkable median overall survival rate in a pivotal cancer trial. Stock analysts predict a strong upside poten

Immutep Limited initiates patient dosing in its TACTI-004 Phase III trial targeting advanced non-small cell lung cancer. Analysts set a promising one-ye

**media[614544]**

Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at t

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with efti will enrol ap

**media[575885]**

SYDNEY, AUSTRALIA, March 20, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; IMMP) (”œImmutep” or ”œthe Company”), a late-stage immunotherapy comp

**media[571871]**

We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at where Immutep Limited (NASDAQ:IMMP) stands against the other long term ASX ...

**media[528993]**

We recently compiled a list of the 10 Best ASX Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Immutep Limited (NASDAQ:IMMP) stands against other best ASX...

Immutep Limited (IMMP) is a promising biotech stock with a strong pipeline and solid financial foundation, making it a buy despite risks.

According to a report by Vanguard published on January 24, Australia's economy is expected to experience a gradual recovery in 2025, following its slowest growth in 32 years in 2024.

**media[521487]**

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches enrolment target of ap